{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-26-000049","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.822899+00:00","generated_at":"2026-05-15T05:49:08.252013+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Autolus Therapeutics dismisses EY UK and appoints EY US as independent auditor","bullets":["Audit committee dismissed EY UK on April 14, 2026; no disagreements or reportable events in prior two fiscal years.","Audit committee appointed EY US as new independent auditor for FY 2026, effective immediately.","EY UK's audit reports for 2024 and 2025 were unqualified; prior material weakness in internal controls disclosed in Q1 2024 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-26-000049","json":"https://secwatch.observer/filing/0001730463-26-000049.json","markdown":"https://secwatch.observer/filing/0001730463-26-000049.md","text":"https://secwatch.observer/filing/0001730463-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000049/0001730463-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000049/autl-20260414.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:49:08.252013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49c20c6f68127eaad771cdc5069bb98f274b30c6","claim":"Autolus Therapeutics plc engaged Ernst & Young LLP (US) as its auditor.","evidence_excerpt":"On April 14, 2026, the Audit Committee approved the engagement of Ernst & Young LLP (US) (“EY US”) as its new independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000049/0001730463-26-000049-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Ernst & Young LLP (US)"}],"fact_type":"auditor_change"},{"claim_id":"709a3e505b1c0f109d9a27698492b51f81af7c6b","claim":"Autolus Therapeutics plc dismissed Ernst & Young LLP (UK) as its auditor.","evidence_excerpt":"(a) Dismissal of Independent Registered Public Accounting Firm. On April 14, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Autolus Therapeutics plc (the “Company”) dismissed Ernst & Young LLP (UK) (“EY UK”) as the Company’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000049/0001730463-26-000049-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Ernst & Young LLP (UK)"},{"label":"Successor","value":"Ernst & Young LLP (US)"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}